IM Injection: Nursing Sites, Technique & Safety | NurseOnShift

💉 Medication administration & injection safety

Intramuscular (IM) Injection: Sites, Technique & Safety

Landmark-based IM administration for nurses: choose the right muscle, protect nerves and vessels, align with organisational medication safety checks, and recognise when systemic allergy requires emergency support.

14 min read

Updated 23 May 2026

Medically Reviewed

Written by

Sid A. Abdala Balal

RN — Registered Nurse

Medically Reviewed by

Dr. Adam Sayedi

MD — Medical Doctor

Overview Indications Contraindications Equipment Pre-injection checks Sites & route choice Site selection ladder Aspiration policy Needle & nerve safety Procedure steps NCLEX practice Post-injection observation Complications & escalation Documentation Clinical pearls FAQ References Related topics Editorial review

Quick facts

Landmark sites

VG · VL · Deltoid

Technique

Non-touch / sterile per policy

Observation

Per drug & local protocol

Sharps

Point-of-use disposal

Key takeaway

Correct landmarks and muscle relaxation matter more than speed: they reduce neurovascular risk and erratic absorption. Pair every IM with epinephrine readiness when allergy risk is relevant, and chart the site and lot when your policy requires traceability.

Overview

Injection Administration (IM) delivers medication deep into skeletal muscle so it can enter circulation reliably when oral or subcutaneous routes are unsuitable. It is a high-frequency skill on medical wards, EDs, immunisation clinics, and mental health units.

IM sits between intradermal (shallow) and intravenous bolus work: you break skin integrity, so infection prevention, five-rights verification, and post-dose monitoring are non-negotiable.

Clinical focus

Think in three layers: rights & reconciliation (including medication reconciliation on admission/transfer), anatomical safety (site, depth, volume), and reaction surveillance (anaphylaxis symptoms, difficulty breathing, swelling).

Indications

Clinical situation	Why IM may be chosen
Rapid onset without IV access	Absorption faster than oral; useful when NPO or vomiting — follow prescriber choice versus IV.
Depot or oily formulations	Some psychotropic or hormonal products are licensed IM; verify monograph.
Antimicrobial therapy	Agents such as ceftriaxone are commonly ordered IM in selected settings — only when diluent, volume, and site match policy.
Analgesia / sedation bridges	Examples include morphine IM where IV is not immediately available — institutional protocols may vary.

Contraindications & pause points

Stop until clarified

Wrong patient, drug, dose, route, or expired product
History of severe IgE-mediated reaction to the same drug class without a documented desensitisation plan
Hard localised swelling, rash, or infection at the intended site suggesting cellulitis

Caution & alternatives

Low muscle mass, severe coagulopathy, or platelet disorder — seek prescriber input
Anticoagulant therapy: balance bleeding risk; apply prolonged pressure; follow local guidance
Repeated IM volumes into the same site — rotate to reduce muscle pain and fibrosis

Escalate early

Unclear order, dilution, or maximum volume per site
Need for Z-track injection technique for an irritating drug you have not been competency-signed for
Patient reports new allergic rash after prior dose

Equipment

Institutional kits differ; assemble before approaching the patient.

✓Prescribed medication and compatible diluent if required

✓Syringe and needle appropriate to viscosity and volume (per policy)

✓Alcohol-based skin antiseptic or chlorhexidine per protocol

✓Sterile gauze / plaster if permitted

✓Sharps container at point of care

✓Clean gloves (and additional PPE if indicated)

✓Observation timer / call bell within reach

✓Emergency tray access pathway when giving high-risk drugs

Injection safety

Align with single-use needles and syringes, avoid two-handed recapping, and segregate waste per infection prevention standards. Report needlestick injuries immediately.

Pre-injection checks

✓Identity (two identifiers) and allergy band / record

✓Vital signs baseline if policy requires (e.g. sedatives)

✓Inspect skin for bruising, tracks, lymphoedema

✓Confirm laterality (deltoid) and mobility for positioning

✓Teach-back on expected fever or local soreness versus urgent symptoms

✓Ensure bathroom / assistance available if post-vaccine vasovagal risk

Sites & route comparison

Choose the smallest muscle that safely accepts the ordered volume. Train specifically for ventrogluteal (VG) landmarks before using it routinely.

Site	When nurses favour it	Watch-outs
Ventrogluteal	Adults needing larger volumes away from sciatic nerve — when staff are landmark-competent	Obesity may alter palpation; reposition if landmarks unclear
Vastus lateralis	Infants/children and many adults; accessible in supine	Ensure lateral thigh mid-segment; avoid proximity to femoral vessels by sticking to taught triangle
Deltoid	Smaller volumes; clinic throughput	Radial nerve territory; avoid if repeated doses cause induration

Deep muscle depot

Moderate–fast absorption for many drugs
Volume limited by muscle size
Landmark accuracy drives safety

SC vs IV push

Adjacent routes

SC: adipose layer; slower; smaller volumes
IV: immediate effect; different calculations & extravasation risk
Never substitute routes without prescriber change

IM site selection ladder

Use this bedside sequence when more than one muscle could work. If any step fails, move down the ladder or clarify the order with pharmacy or the prescriber.

Confirm volume and drug class

Check the monograph and local maximum per site. Large or irritating volumes may exclude deltoid and favour vastus lateralis (VL) or ventrogluteal (VG) when staff are landmark-competent.

Match mobility and positioning

VL suits supine or seated patients; VG needs side-lying or prone positioning you can maintain safely. Deltoid works for smaller volumes when the arm can relax.

Inspect tissue and prior doses

Reject induration, bruising, lymphoedema, or infection. Review the MAR for recent IM sites and rotate to healthy muscle.

Re-palpate landmarks if uncertain

Obesity, oedema, or contractures can obscure landmarks—reposition, use taught bony references, or ask a second nurse to confirm before inserting.

When to pause

If landmarks remain unclear, the patient cannot tolerate positioning, or the ordered volume exceeds policy for the only accessible site, do not proceed—contact the prescriber or pharmacist for an alternative route or formulation.

Aspiration policy at the bedside

Aspiration practice for IM injections is not uniform across vaccines, antibiotics, analgesics, and depot psychotropics. Follow, in order: manufacturer information for use, institutional protocol for that drug class, then skills-lab teaching for non-immunisation IM.

If blood returns on aspiration

Stop injecting, withdraw slightly or remove the needle per protocol, discard supplies, and prepare a new dose if policy allows. Document the event and reassess site selection.

Never assume “no aspiration for all IM”

Applying immunisation guidance to sedatives, antibiotics, or depot injections without verification is a common medication-safety error.

Needle length & neurovascular safety

Needle gauge and length should match adipose thickness, muscle depth, and viscosity—follow device education and policy rather than one universal needle for every adult.

Patient factor	Nursing consideration
Higher adipose thickness	May need longer needle or spreading technique taught locally so the depot reaches muscle; avoid deltoid if depth is inadequate.
Very thin muscle mass	Confirm site still accepts ordered volume; consider prescriber review for SC or IV alternatives.
Anticoagulation / low platelets	Balance bleeding risk with clinical need; prolonged pressure; monitor for expanding bruising.
Paraesthesia during insertion	Stop, withdraw, and select a new site—may indicate nerve contact.

Irritating agents (for example some iron preparations) may require Z-track injection when you are competency-signed and policy mandates it.

Procedure steps

Preparation

Perform the medication safety bundle

Complete rights checks, screen allergies, and involve a second verifier when high-alert medication policy demands it.

Explain and position

Describe transient sting, post-dose muscle soreness, and when to call for help. Position to relax the chosen muscle.

Hand hygiene & draw-up

Perform hand hygiene, prepare the dose using non-touch technique, and label the syringe if policy requires multi-step preparation.

Sterility checkpoint

Before approaching the patient, confirm the needle is intact, the medication matches the MAR/eMAR, and no supply has touched a non-sterile surface.

Implementation

Expose & cleanse skin

Allow antiseptic to dry fully; do not blow or fan the site.

Stabilise & insert

Use the needle bevel and entry angle taught in your skills lab. Spread subcutaneous tissue in obese patients if technique specifies.

Aspirate (per policy)

Immunisation programmes may omit aspiration; other drugs may still specify a brief negative aspiration. When blood appears, withdraw slightly, abort or reposition per protocol, and replace supplies.

Inject slowly & evenly

Rapid boluses increase pain and tissue shear. Pause if the patient reports severe pain or paraesthesia.

Completion

Withdraw, pressure, sharps

Engage safety device, dispose immediately, and apply pressure to reduce bruising.

Initial observation

Stay with the patient through the immediate window; watch for anaphylaxis-type symptoms, vasovagal response, and respiratory compromise.

Sequence at a glance

Rights + allergies

Landmark + prep

Insert + inject

Withdraw + sharps

Observe

Document

Post-injection observation window

Match monitoring intensity to drug class. Vaccine programmes often specify a timed seated observation; opioid IM doses may require respiratory rate and sedation scoring per policy.

Treat suspected anaphylaxis as an emergency

Call resuscitation team per local pathway, administer epinephrine when authorised, position supine with legs elevated if tolerated, and prepare for airway support. Do not leave the patient to “watch from the desk.”

If delayed fever, spreading rash, or swelling appears hours later, notify the clinician — consider blood cultures or complete blood count only when ordered.

Complications & escalation

Finding	Concern	Nursing action
Rising pain with neuro symptoms	Nerve injury / compartment issue	Stop further IM in that limb; urgent medical review
Expanding hematoma	Coagulopathy or arterial bleed	Pressure, monitoring, labs if ordered, escalate
Warm erythematous tracking	Cellulitis or staphylococcal soft-tissue infection	Mark borders if policy allows; wound culture if ordered
Systemic inflammatory decline	Possible sepsis	Escalate via NEWS/MEWS pathway; support ABCs

Documentation

Example charting phrase

“19/05/2026 10:20 — Ceftriaxone 1 g IM administered L vastus lateralis after negative aspiration per protocol. Lot AB123, exp 08/2027. Patient tolerated; observed 15 minutes without respiratory distress or urticaria. Educated on delayed reaction follow-up.”

Medication name, dose, route, site, time
Lot, expiry, diluent (when required)
Needle length/gauge if mandated for vaccine audits
Patient response and observation duration
Adverse events and actions taken

Clinical pearls

Bundle teaching with general medication administration principles so patients understand why oral tablets cannot replace depot IM.
When labs are needed after reaction, coordinate venipuncture timing with the team so monitoring is continuous.
Rotate sites for repeated injections; map prior doses in the MAR to avoid fibrotic pockets.
Use interpreter services for consent and education — do not rely on minors for clinical translation.

NCLEX-Style Case Review

NCLEX-style clinical judgment practice — Landmark errors and skipped allergy checks change absorption and escalation—rehearse intramuscular (IM) injection, including a priority action, select-all-that-apply cue recognition, trend interpretation after intervention, and matrix escalation matching (recognise cues → analyse → prioritise → act → evaluate outcomes).

Unfolding case — emergency department. Ms. Patel, 28, has pyelonephritis and is ordered ceftriaxone 1 g IM after IV access failed twice. Allergy band documents childhood penicillin rash only (no anaphylaxis). BMI 31; left thigh accessible in semi-Fowler. MAR shows morphine IM given to the same leg yesterday. Pharmacy supplied diluent and a 21-gauge needle per protocol; observation bay available.

Question 1 — Priority action

Which action should the nurse initiate first to reduce patient risk?

Inject into yesterday’s IM site to avoid exposing a new area. Skip allergy verification because the reaction was only a rash years ago. Complete five rights, clarify non–IgE penicillin cross-reactivity per protocol, inspect the left thigh for induration from yesterday’s IM, and select a fresh vastus lateralis site with taught landmarks. Use the deltoid without palpating landmarks to finish quickly in a busy ED.

Question 2 — Select all that apply

Select all that apply — which cues should the nurse recognise before IM administration?

Prior IM dose to the same limb within 24–48 h increases pain and fibrosis risk Ordered volume and dilution must match pharmacy and institutional maximum per site Patient prefers evening injections for convenience Active warmth, erythema, or tracking at the planned site suggests infection Aspiration steps depend on product monograph and policy—not one rule for every IM drug

Question 3 — Trend interpretation

Fifteen minutes after ceftriaxone 1 g IM in the right vastus lateralis (negative aspiration per protocol):

Trend snapshot
Vitals: BP 118/72 mmHg, HR 88/min, RR 16/min, SpO₂ 98% on room air
Injection site: mild tenderness, no swelling; gauze dry
Symptoms: denies lip or tongue swelling, wheeze, or dizziness
Labs: temperature 38.1 °C pre-dose (infection context)
Plan: observe per ED policy; oral antibiotics discussed

Select all that apply — which nursing actions are appropriate now?

Continue protocol observation; document site, lot, dilution, aspiration result, and tolerance Discharge immediately without documentation because vitals are stable Teach to report delayed rash, spreading redness, or breathing change after IM antibiotics Evaluate outcomes by comparing next vital signs, site inspection, and whether systemic allergy signs develop during the observation window Activate emergency response if urticaria, stridor, or hypotension emerges

Question 4 — Matrix judgment

For each situation during or after IM injection, select the best nursing action category (one per row).

Situation	Continue routine monitoring / supportive care	Notify clinician / urgent same-day pathway	Activate rapid response / emergency escalation
Mild IM site tenderness without neuro symptoms; vitals stable after observation period
Sharp shooting pain down the leg with foot drop during IM insertion—needle withdrawn
Expanding warm erythema tracking from IM site 24 h later; patient febrile
Urticaria, audible wheeze, and BP 82/48 mmHg within 5 min of IM antibiotic

On a small screen, swipe or scroll sideways to see the full table.

Answer key & rationale

Next step Timed NCLEX Next Gen–style scenarios on NurseOnShift

Frequently asked questions

FAQ

Do I need to aspirate before every IM injection?

Practice varies by organisation, product monograph, and public-health immunisation guidance. Follow local policy and manufacturer directions rather than assuming one rule for all IM medications.

Which IM site is safest for adults?

Many references favour the ventrogluteal site when staff are trained in its landmarks because it is distant from major nerves and vessels, but the best site also depends on medication volume, muscle mass, mobility, and clinician familiarity. Institutional protocols may vary.

How long should I observe after an IM injection?

Observation time depends on the drug (for example vaccines versus depot injections) and local policy. Use a defined observation area for patients at higher allergy risk and document the monitoring period.

What if the patient refuses the IM route?

Explore reasons, offer information within scope, and involve the prescriber if an alternative route or formulation exists. Do not coerce; document the discussion and outcome.

What should I do after a needlestick?

Encourage bleeding at the site if appropriate, wash with soap and water, report immediately through occupational health or local sharps injury pathway, and do not delay risk assessment.

When is Z-track used for IM injections?

Z-track can limit superficial tracking of irritating medications such as some iron preparations. Use only when trained and when policy or the medication programme specifies it.

References

The Royal Marsden Manual of Clinical Nursing Procedures — official procedures hub (RMM Online).
https://www.rmmonline.co.uk/contents/procedures
Centers for Disease Control and Prevention (CDC). Safe injection practices and your health.
https://www.cdc.gov/injection-safety/index.html
StatPearls [Internet]. Intramuscular injection — NCBI Bookshelf clinical summary.
https://www.ncbi.nlm.nih.gov/books/NBK556121/
OpenStax. Clinical Nursing Skills — open educational resource (parenteral medication skills).
https://openstax.org/details/books/clinical-nursing-skills
NCBI Bookshelf. Nursing Skills, Chapter 18 — administration of parenteral medications.
https://www.ncbi.nlm.nih.gov/books/NBK593214/
CDC / NIOSH. Stop Sticks — sharps injury prevention campaign resources.
https://www.cdc.gov/niosh/stopsticks/

Editorial standards & medical review

About the author: Sid A. Abdala Balal, RN, writes evidence-based nursing education focused on practical bedside skills, patient safety, and clinical decision support for nurses.

Medical review: This guide is reviewed by Dr. Adam Sayedi, MD, for clinical accuracy, clarity, and alignment with current nursing standards for intramuscular injection.

Policies: Medical Review Process · Editorial Policy · Correction Policy